In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

—According to new research, oral vertical dyskinesia (OVD), also known by the older term “rabbit syndrome,” may be part of a spectrum of symptoms of drug-induced parkinsonism and tardive dyskinesia, ...

The gold standard is the Abnormal Involuntary Movement Scale, or the AIMS, although generally we kind of want to avoid premature TD labels, and we want to ensure that there's a causal link, in this ...

Whether someone you know already has tardive dyskinesia (TD) or they're at risk for it because of a medicine they take, you might wonder how you can help. People who have this movement disorder need a ...

Tardive dyskinesia is a hyperkinetic movement disorder that causes faces to move involuntarily and abnormally. It is considered to be a drug-induced movement disorder. Movements often occur in the ...

Tracking your tardive dyskinesia symptoms provides insight into what’s going on. Tardive dyskinesia (TD) is a movement disorder that causes certain uncontrollable movements in different parts of the ...

Tardive dyskinesia (TD) is a severe and often irreversible movement disorder resulting from prolonged exposure to dopamine receptor-blocking agents (DRBAs), most notably antipsychotics. Characterized ...

Tardive dyskinesia can affect many areas of your life, including your social life and self-confidence. Learning how to manage these effects can help improve your overall well-being and daily ...

Christoph U. Correll, MD, professor of psychiatry at The Zucker School of Medicine at Hofstra/Northwell and professor and chair of the department of child and adolescent psychiatry at Charité ...

The US Food and Drug Administration (FDA) has approved deutetrabenazine extended-release tablets (Austedo XR, Teva), a new once-daily formulation of the drug for adults with tardive dyskinesia (TD) or ...